Announcements & Media Coverage

Hemogenyx Pharmaceuticals plc (the “Company”)   CDX Development Agreement Extension   Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, announces that it has extended its development agreement (“Agreement”) with a leading global pharmaceutical company (“GlobalCo”) engaged in the research, development, manufacture and marketing of pharmaceutical products....